Prof. Feng-Ming (Spring) Kong, MD, PhD, FACR, FAAWR and FASTRO, Master in clinical trial design and data analysis, American Board Certified Radiation Oncologist, Fellow of the American College of Radiology (FACR), Fellow of the American Association of Women Radiologists (FAAWR) and Fellow of American Society for Radiation Oncology (FASTRO), is a clinical professor, Director of Imaging and Blood Biomarker Group, Director of Thoracic Oncology Center and Deputy Cancer Center Director, HKU Shen-Zhen Hospital, Li Ka Shing faculty of Medicine, the University of Hong Kong. Professor Kong is a graduate of Radiation Oncology Residency Program from the Washington University in St. Louis  and also had Radiation Oncology Residency training from Shanghai Cancer Hospital/Fudan University and postdoctoral training at Duke University. As a radiation oncologist in United States, Professor Kong has served as an expert panelist of National Cancer Network (NCCN) Guideline and ACR radiation oncology practice appropriateness guidelines. Dr. Kong received numerous awards including prestigious young investigator award and career developmental award from American Society of Clinical Oncology (ASCO), NIH R21 and R01 as the Principal Investigator and P01 as a Key Investigator from NIH/NCI of the United States. Professor Kong served as the leader of thoracic radiation oncology research program, director of Clinical Research, Chair of Radiation Oncology Department and associate director of Cancer Center, Co-Leader of MultiD Thoracic Oncology Program. She served as the President of American Association for Women Radiologists Radiation Oncologists. During her tenure in Hong Kong China, she has secured funding of 40+ million RMB including China NSF and a platform grant of high-level talents on clinical trial. Upto October 2023, Professor Kong has published 280 scientific publications, with over 10,000 citations, was listed among the top 1% scientists in the field of lung cancer in 2020 and 1% published in radiation pneumonitis in 2021. Professor Kong has served as a reviewer for more than 20 Journals, and served as a member of editorial boards of top oncology journals like Journal of Clinical Oncology (JCO, IF 50s in 2023) and the best Radiation Oncology Journal, the International Journal of Radiation Oncology (Red Journal,IF8.0). She is currently as an associate editor of the Journal of the National Cancer Centre (JNCC), the official Journal of China Health administration commission, Co-Editor-in-Chief for Intelligent Oncology sponsored the Chinese Anti-Cancer Association and editorial roles in other journals like frontier Oncology. She is the founding President of the Sino-American Network of Radiation Oncology (SANTRO), the inaugural Chair of the SANTRO Board Directors. Professor Kong is Chair of the WHO STAR Oncology Guidelines Assessment Commission of the WHO Collaborating Centre, and the President of the Global Cancer Collaborative Group (GCOG).

Below is the list of Prof. Kong's titles :

Leader of A Peacock Project on Innovative Clinical Trial Platform on Radiation and Immunotherapy
Leader of A Peacock Project on RT and Immunotherapy
B-file talents of Health Commission of Shenzhen 
Professor of Clinical Oncology/Deputy Director of Oncology Medical Center/Director of Thoracic Oncology Spelciaty, HKU-SZH, The University of Hong Kong
President of Global Collaborative Oncology Group (GCOG) （2019-present）
Co-chair for ACLC 2024
Deputy Director of Overseas Expert Committee of China CSCO Clinical Oncology Society
STAR Guideline Chair for Oncology
Fellow of American College of Radiology (FACR)
Fellow of American association for Women Radiologists/Radiation Oncologists (FAAWR)
Fellow of American Society of Radiation Oncology（FASTRO）
Advanced Radiation Technology (ART) , Expert leader on RT OAR contouring guideline(2022)
Expert reviewer for ASTRO guideline on lung cancer (2020-present)
Served as expert panelist for NCCN guideline (most commonly worldwide) (2008-2013) 
Served as NIH/NCI R21/P01/R01 funded principal investigator,Received numerous awards such as ASCO YIA and ASCO CDA
260+ publications (10000+ citations), listed in the top 1% scholar for citation in 2020
In 2021, the peer published radiation pneumonia up to 1% of scholars
Director of innovative adaptive radiotherapy RTOG1106 in US
Served as editorial board member of many top Journals including Red Journal, clinical lung cancer, JCO (IF=50) 
National PI of RTOG1106 on adaptive RT, translational research co-chair for RTOG SBRT trials RTOG618 and RTOG813.
Served as Chair of Radiation Oncology department and Associate Cancer Center Director at Medical College of Georgia (2013-2016)
Served as a co-leader of Thoracic Oncology Program at Indiana University School of Medicine and Cancer Center of Georgia (2016-2018)
President of AAWR  （2015） President of AAWR Research and Foundation (2016)
Founding President of SANTRO (2008-2010) and Chair of SANTRO Board Directors (2006-2012)

1. Chiang CL, Chan KSK, Chiu KWH, Lee FAS, Chen W, Wong NSM, Ho RLM, Lee VWY, Man K, Kong FMS, Chan ACY. Complete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma. JAMA Oncol. 2024 Nov 1;10(11):1548-1553. doi: 10.1001/jamaoncol.2024.4085. PMID: 39325464; PMCID: PMC11428022.
2. Chiang CL, Chiu KWH, Chan KSK, Lee FAS, Li JCB, Wan CWS, Dai WC, Lam TC, Chen W, Wong NSM, Cheung ALY, Lee VWY, Lau VWH, El Helali A, Man K, Kong FMS, Lo CM, Chan AC. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):169-178. doi: 10.1016/S2468-1253(22)00339-9. Epub 2022 Dec 15. PMID: 36529152.
3. Zhao CN, Li SS, Yau T, Chen WQ, Ji R, Guan XY, Kong FS. Phocaeicola vulgatus induces immunotherapy resistance in hepatocellular carcinoma via reducing indoleacetic acid production. Cell Rep Med. 2025 Oct 21;6(10):102370. doi: 10.1016/j.xcrm.2025.102370. Epub 2025 Sep 25. PMID: 41005300; PMCID: PMC12629828.
4. Zhou L, Liu Y, Wu Y, Yang X, Spring Kong FM, Lu Y, Xue J. Low-dose radiation therapy mobilizes antitumor immunity: New findings and future perspectives. Int J Cancer. 2024 Apr 1;154(7):1143-1157. doi: 10.1002/ijc.34801. Epub 2023 Dec 7. PMID: 38059788.
5. Milano MT, Mavroidis P, Yorke E, Ryckman J, Kong FS, Grimm J, Marks LB. In Reply to Onjukka et al. Int J Radiat Oncol Biol Phys. 2024 Mar 15;118(4):1145-1146. doi: 10.1016/j.ijrobp.2023.08.067. Epub 2024 Feb 22. PMID: 38401970.
6. Kong FS, Hu C, Pryma DA, Duan F, Matuszak M, Xiao Y, Ten Haken R, Siegel MJ, Hanna L, Curran WJ, Dunphy M, Gelblum D, Piert M, Jolly S, Robinson CG, Quon A, Loo BW, Srinivas S, Videtic GM, Faria SL, Ferguson C, Dunlap NE, Kundapur V, Paulus R, Siegel BA, Bradley JD, Machtay M. Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung Cancer. J Clin Oncol. 2024 Nov 20;42(33):3935-3946. doi: 10.1200/JCO.24.00022. Epub 2024 Oct 4. PMID: 39365957; PMCID: PMC11781790.
7. Zhou H, Wang SC, Lee TTL, Ye ZH, Fang CB, Wai AKC, Hu C, Kong FS. Combination of Radiotherapy and Immunotherapy in Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2026 May 1;12(5):506-516. doi: 10.1001/jamaoncol.2026.0392. PMID: 41885834; PMCID: PMC13022771.
8. Zhao CN, Chiang CL, Chiu WK, Chan SK, Li CJ, Chen WW, Zheng DY, Chen WQ, Ji R, Lo CM, Jabbour SK, Chan CA, Kong FS. Treatments of transarterial chemoembolization (TACE), stereotactic body radiotherapy (SBRT) and immunotherapy reshape the systemic tumor immune environment (STIE) in patients with unresectable hepatocellular carcinoma. J Natl Cancer Cent. 2024 Nov 28;5(1):38-49. doi: 10.1016/j.jncc.2024.06.007. PMID: 40040869; PMCID: PMC11873621.
9. Zhang Y, Hu YF, Ma L, Wu Y, Chao D, Chen X, Xu Z, Su X, Dai W, Huang J, Fu P, Kong FS. A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028. Front Immunol. 2025 Aug 21;16:1538032. doi: 10.3389/fimmu.2025.1538032. PMID: 40918097; PMCID: PMC12408632.
10. Chen WW, Chu TSM, Xu L, Zhao CN, Poon WS, Leung GK, Kong FS. Immune related biomarkers for cancer metastasis to the brain. Exp Hematol Oncol. 2022 Dec 16;11(1):105. doi: 10.1186/s40164-022-00349-z. PMID: 36527157; PMCID: PMC9756766.
11. Kong FS. Precision radiation therapy in the modern era of multidisciplinary care in oncology: What matters to our patients and beyond? J Natl Cancer Cent. 2024 May 11;4(3):260-262. doi: 10.1016/j.jncc.2024.05.004. PMID: 39281719; PMCID: PMC11401493.
12. Zhou L, Liu Y, Xing Z, Wu Y, Yang X, Chen S, Kang K, Wang M, Zhou Z, Huang M, Gong Y, Zhou L, Zhou X, Li J, Yao Z, Zheng Q, Kong FS, Niedermann G, Luo R, Lu Y, Xue J. Low-dose radiotherapy synergizes with PD-1 blockade to achieve durable survival in advanced NSCLC through antitumor neutrophil programming. Signal Transduct Target Ther. 2026 May 7;11(1):170. doi: 10.1038/s41392-026-02712-6. PMID: 42091852; PMCID: PMC13149844.
13. Hu Y, Zhao C, Ji R, Chen W, Shen Q, Chiang CL, Chan J, Ma L, Yang H, Wong T, Ellsworth S, Lo CM, Dawson LA, Kong FS. The role of stereotactic body radiotherapy in hepatocellular carcinoma: guidelines and evidences. J Natl Cancer Cent. 2022 Jun 12;2(3):171-182. doi: 10.1016/j.jncc.2022.05.002. PMID: 39036452; PMCID: PMC11256675.
14. Abdel-Wahab M, Coleman CN, Eriksen JG, Lee P, Kraus R, Harsdorf E, Lee B, Dicker A, Hahn E, Agarwal JP, Prasanna PGS, MacManus M, Keall P, Mayr NA, Jereczek-Fossa BA, Giammarile F, Kim IA, Aggarwal A, Lewison G, Lu JJ, Guedes de Castro D, Kong FS, Afifi H, Sharp H, Vanderpuye V, Olasinde T, Atrash F, Goethals L, Corn BW. Addressing challenges in low-income and middle-income countries through novel radiotherapy research opportunities. Lancet Oncol. 2024 Jun;25(6):e270-e280. doi: 10.1016/S1470-2045(24)00038-X. PMID: 38821101; PMCID: PMC11382686.
15. Zeng H, De Ruysscher DKM, Hu X, Zheng D, Yang L, Ricardi U, Kong FS, Hendriks LEL. Radiotherapy for small cell lung cancer in current clinical practice guidelines. J Natl Cancer Cent. 2022 Mar 3;2(2):113-125. doi: 10.1016/j.jncc.2022.02.003. PMID: 39034955; PMCID: PMC11256623.
16. Ruan J, Zhao Z, Qian Y, Xu R, Liao G, Kong FS. The predictive role of soluble programmed death ligand 1 in digestive system cancers. Front Oncol. 2023 Jul 13;13:1170220. doi: 10.3389/fonc.2023.1170220. PMID: 37519785; PMCID: PMC10374258.
17. Cheung BMF, Yuen KK, Luk MY, Leung DKC, Kong FS, Lee VH. Lymphocyte nadir and recovery dynamics for locally advanced thoracic malignancies undergoing concurrent chemo-irradiation: Establishment of organs-at-risk constraints. Radiother Oncol. 2025 Sep;210:111009. doi: 10.1016/j.radonc.2025.111009. Epub 2025 Jun 26. PMID: 40581215.
18. Chen W, Yang L, Lee VH, Xu L, Ma L, Ye Z, Xu W, Zhao C, Zheng D, Kiang KM, Sun S, Qu Y, Zha J, Pang D, Zhang Y, Liang Z, Lin W, Zhang J, Zhang J, Luo M, Xu Z, Li D, Liang X, Leung GK, Helali AE, Che C, Feng-Ming Spring Kong. Indoleamine 2,3-dioxygenase 1-mediated immune suppressive status is positively associated with brain metastasis in patients with non-small cell lung cancer. J Natl Cancer Cent. 2024 Dec 15;5(2):179-192. doi: 10.1016/j.jncc.2024.12.004. PMID: 40265090; PMCID: PMC12010389.
19. Milano MT, Mavroidis P, Ryckman J, Yorke E, Doucette C, Mahadevan A, Kapitanova I, Spring Kong FM, Marks LB, Grimm J. Radiation-induced inferior brachial plexopathy after stereotactic body radiotherapy: Pooled analyses of risks. Radiother Oncol. 2023 May;182:109583. doi: 10.1016/j.radonc.2023.109583. Epub 2023 Feb 25. PMID: 36842665; PMCID: PMC10501316.
20. Chen F, Ma L, Wang Q, Zhou M, Nong Y, Jing H, Han Y, Liu Y, Hu Y, Yu H, Fu P, Kong FS. Chemotherapy is a risk factor of lymphopenia before adjuvant radiotherapy in breast cancer. Cancer Rep (Hoboken). 2022 Jul;5(7):e1525. doi: 10.1002/cnr2.1525. Epub 2021 Aug 14. PMID: 34390318; PMCID: PMC9327667.
21. Milano MT, Doucette C, Mavroidis P, Yorke E, Ryckman J, Mahadevan A, Kapitanova I, Kong FS, Grimm J, Marks LB. Hypofractionated Stereotactic Radiation Therapy Dosimetric Tolerances for the Inferior Aspect of the Brachial Plexus: A Systematic Review. Int J Radiat Oncol Biol Phys. 2024 Mar 15;118(4):931-943. doi: 10.1016/j.ijrobp.2022.11.012. Epub 2023 Jan 20. PMID: 36682981; PMCID: PMC11325459.
22. Yang D, Ren G, Ni R, Huang YH, Lam NFD, Sun H, Wan SBN, Wong MFE, Chan KK, Tsang HCH, Xu L, Wu TC, Kong FS, Wáng YXJ, Qin J, Chan LWC, Ying M, Cai J. Deep learning attention-guided radiomics for COVID-19 chest radiograph classification. Quant Imaging Med Surg. 2023 Feb 1;13(2):572-584. doi: 10.21037/qims-22-531. Epub 2022 Nov 21. PMID: 36819269; PMCID: PMC9929417.
23. Yu H, Chen F, Lam KO, Yang L, Wang Y, Jin JY, Ei Helali A, Kong FS. Potential Determinants for Radiation-Induced Lymphopenia in Patients With Breast Cancer Using Interpretable Machine Learning Approach. Front Immunol. 2022 Jun 21;13:768811. doi: 10.3389/fimmu.2022.768811. PMID: 35799797; PMCID: PMC9253393.
24. Zeng H, Zheng D, Witlox WJA, Levy A, Traverso A, Kong FS, Houben R, De Ruysscher DKM, Hendriks LEL. Risk Factors for Brain Metastases in Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Front Oncol. 2022 Jun 10;12:889161. doi: 10.3389/fonc.2022.889161. PMID: 35756675; PMCID: PMC9226404.
25. Liu D, Liu H, Gan J, Zeng S, Zhong F, Zhang B, Zhang Z, Zhang S, Jiang L, Wang G, Chen Y, Kong FS, Fang W, Wang L. LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC. Front Pharmacol. 2022 Jun 23;13:918317. doi: 10.3389/fphar.2022.918317. PMID: 35814257; PMCID: PMC9260114.
26. Sun H, Ren G, Teng X, Song L, Li K, Yang J, Hu X, Zhan Y, Wan SBN, Wong MFE, Chan KK, Tsang HCH, Xu L, Wu TC, Kong FS, Wang YXJ, Qin J, Chan WCL, Ying M, Cai J. Artificial intelligence-assisted multistrategy image enhancement of chest X-rays for COVID-19 classification. Quant Imaging Med Surg. 2023 Jan 1;13(1):394-416. doi: 10.21037/qims-22-610. Epub 2022 Nov 10. PMID: 36620146; PMCID: PMC9816729.
27. Chen F, Hui TSK, Ma L, Nong Y, Han Y, Jing H, Lee EKW, Xu Z, Fu P, Chang ATY, Hsue V, Kong FS. Real-World Practice of Hypofractionated Radiotherapy in Patients With Invasive Breast Cancer. Front Oncol. 2022 Feb 3;12:811794. doi: 10.3389/fonc.2022.811794. PMID: 35186748; PMCID: PMC8852155.
28. Huang YH, Teng X, Zhang J, Chen Z, Ma Z, Ren G, Kong FS, Ge H, Cai J. Respiratory Invariant Textures From Static Computed Tomography Scans for Explainable Lung Function Characterization. J Thorac Imaging. 2023 Sep 1;38(5):286-296. doi: 10.1097/RTI.0000000000000717. Epub 2023 May 29. PMID: 37265243.
29. Meng Y, Sun H, Wang S, Yang H, Kong FS. Treatment-Related Pneumonitis of EGFR Tyrosine Kinase Inhibitors Plus Thoracic Radiation Therapy in Patients With Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys. 2024 Feb 1;118(2):415-426. doi: 10.1016/j.ijrobp.2023.09.009. Epub 2023 Sep 14. PMID: 37716460.
30. Liao G, Zhao Z, Qian Y, Ling X, Chen S, Li X, Kong FS. Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Front Oncol. 2021 Dec 23;11:774131. doi: 10.3389/fonc.2021.774131. PMID: 35004295; PMCID: PMC8732757.
31. Lan Y, Pi W, Zhou Z, Meng Y, DanMei, Xu Y, Xia X, WeiWang, Yang H, Spring Kong FM. Effect of radiation fractionation on IDO1 via the NF-κB/COX2 axis in non-small cell lung cancer. Int Immunopharmacol. 2023 Nov;124(Pt B):110956. doi: 10.1016/j.intimp.2023.110956. Epub 2023 Sep 24. PMID: 37751656.
32. Zhang J, Teng X, Lam S, Sun J, Cheung AL, Ng SC, Lee FK, Au KH, Yip CW, Lee VH, Lin Z, Liang Y, Yang R, Han Y, Zhang Y, Kong FS, Cai J. Quantitative Spatial Characterization of Lymph Node Tumor for N Stage Improvement of Nasopharyngeal Carcinoma Patients. Cancers (Basel). 2022 Dec 30;15(1):230. doi: 10.3390/cancers15010230. PMID: 36612236; PMCID: PMC9818273.
33. Ellsworth SG, Ross A, Shiue KRY, Murthy P, Byrne-Steel ML, Patel R, Zellars RC, Kong FS, Miller A, Russ KA, Lotze MT. Survey of Changes in Absolute Lymphocyte Counts and Peripheral Immune Repertoire Diversity after External Beam Radiotherapy. Radiat Res. 2024 Dec 1;202(6):837-846. doi: 10.1667/RADE-24-00010.1. PMID: 39472998.
34. Niu GM, Gao MM, Wang XF, Dong Y, Zhang YF, Wang HH, Guan Y, Cheng ZY, Zhao SZ, Song YC, Tao Z, Zhao LJ, Meng MB, Spring Kong FM, Yuan ZY. Dosimetric analysis of brachial plexopathy after stereotactic body radiotherapy: Significance of organ delineation. Radiother Oncol. 2024 Jan;190:110023. doi: 10.1016/j.radonc.2023.110023. Epub 2023 Nov 22. PMID: 37995850.
35. Ren G, Li B, Lam SK, Xiao H, Huang YH, Cheung AL, Lu Y, Mao R, Ge H, Kong FS, Ho WY, Cai J. A Transfer Learning Framework for Deep Learning-Based CT-to-Perfusion Mapping on Lung Cancer Patients. Front Oncol. 2022 Jul 1;12:883516. doi: 10.3389/fonc.2022.883516. PMID: 35847874; PMCID: PMC9283770.
36. Huang YH, Ren G, Xiao H, Yang D, Kong FS, Ho WY, Cai J. Volumetric multiphase ventilation imaging based on four-dimensional computed tomography for functional lung avoidance radiotherapy. Med Phys. 2022 Nov;49(11):7237-7246. doi: 10.1002/mp.15847. Epub 2022 Jul 22. PMID: 35841346.
37. Ye M, Tong L, Zheng X, Wang H, Zhou H, Zhu X, Zhou C, Zhao P, Wang Y, Wang Q, Bai L, Cai Z, Kong FS, Wang Y, Li Y, Feng M, Ye X, Yang D, Liu Z, Zhang Q, Wang Z, Han S, Sun L, Zhao N, Yu Z, Zhang J, Zhang X, Katz RL, Sun J, Bai C. A Classifier for Improving Early Lung Cancer Diagnosis Incorporating Artificial Intelligence and Liquid Biopsy. Front Oncol. 2022 Mar 2;12:853801. doi: 10.3389/fonc.2022.853801. PMID: 35311112; PMCID: PMC8924612.
38. Lam NFD, Sun H, Song L, Yang D, Zhi S, Ren G, Chou PH, Wan SBN, Wong MFE, Chan KK, Tsang HCH, Kong FS, Wáng YXJ, Qin J, Chan LWC, Ying M, Cai J. Development and validation of bone-suppressed deep learning classification of COVID-19 presentation in chest radiographs. Quant Imaging Med Surg. 2022 Jul;12(7):3917-3931. doi: 10.21037/qims-21-791. PMID: 35782269; PMCID: PMC9246721.'
39. Chen J, Zhu X, Jin JY, Kong FS, Yang G. Artificial intelligence-powered innovations in radiotherapy: boosting efficiency and efficacy. Med Rev (2021). 2025 Feb 28;5(4):348-351. doi: 10.1515/mr-2025-0007. PMID: 40838109; PMCID: PMC12362058.
40. Zhang J, Yang L, Li H, Chan JW, Lee EKW, Liu M, Ma L, Liu Q, Jin JY, Fu P, Xu Z, Kong FS. Dosimetric Effect of Thymus and Thoracic Duct on Radiation-Induced Lymphopenia in Patients With Primary Lung Cancer Who Received Thoracic Radiation. Adv Radiat Oncol. 2023 May 1;8(6):101260. doi: 10.1016/j.adro.2023.101260. PMID: 38047216; PMCID: PMC10692302.
41. Chiang CL, Lam TC, Li JCB, Chan KSK, El Helali A, Lee YYP, Law LHT, Zheng D, Lo AWI, Kam NW, Li WS, Cheung AKW, Chow JCH, Chan SPC, Lai JWY, Lee SWM, Kong FS, Ng WT, Kwong DLW, Lee AWM. Efficacy, safety, and correlative biomarkers of bintrafusp alfa in recurrent or metastatic nasopharyngeal cancer patients: a phase II clinical trial. Lancet Reg Health West Pac. 2023 Sep 6;40:100898. doi: 10.1016/j.lanwpc.2023.100898. PMID: 37701718; PMCID: PMC10493598.
42. Chen F, Jin JY, Hui TSK, Jing H, Zhang H, Nong Y, Han Y, Wang W, Ma L, Yi F, Chen Q, Zhang Y, Fu P, Yang L, Xu Z, Kong FS. Radiation Induced Lymphopenia Is Associated With the Effective Dose to the Circulating Immune Cells in Breast Cancer. Front Oncol. 2022 Apr 28;12:768956. doi: 10.3389/fonc.2022.768956. PMID: 35600350; PMCID: PMC9118537.
43. Chiang CL, Lee FAS, Chan KSK, Lee VWY, Chiu KWH, Ho RLM, Fong JKS, Wong NSM, Yip WWL, Yeung CSY, Lau VWH, Man K, Kong FMS, Chan ACY. Survival Outcome Analysis of Stereotactic Body Radiotherapy and Immunotherapy (SBRT-IO) versus SBRT-Alone in Unresectable Hepatocellular Carcinoma. Liver Cancer. 2023 Oct 1;13(3):265-276. doi: 10.1159/000533425. PMID: 38756147; PMCID: PMC11095610.
44. Wang Y, Song Y, Wang R, Wu Y, Li M, Xu K, He R, Wang Z, Li Q, Kong FS, Wang T. Clinical factors and major pathological response after neoadjuvant chemoimmunotherapy in potentially resectable lung squamous cell carcinoma. Front Oncol. 2024 Apr 12;14:1265228. doi: 10.3389/fonc.2024.1265228. PMID: 38680859; PMCID: PMC11045983.
45. Yu Y, Fu P, Jin JY, Gao S, Wang W, Machtay M, Wang L, Kong FS, Yu J. Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC. Radiother Oncol. 2021 Sep;162:26-33. doi: 10.1016/j.radonc.2021.06.020. Epub 2021 Jun 15. PMID: 34139210.
46. Yang L, Xu Z, Ma L, Liu Q, Chang ATY, Wang Q, Zha J, Zhang J, Jiang X, Zhang J, Kong FS, Guo L. Early onset of severe lymphopenia during definitive radiotherapy correlates with mean body dose and predicts poor survival in cervical cancer. Cancer Biomark. 2022;34(1):149-159. doi: 10.3233/CBM-210292. PMID: 35094986; PMCID: PMC9108612.
47. Li Y, Chen H, Shen Q, Liu Y, Li P, Ma Y, Wang Y, Li S, Yan X, Liu L, Shuai J, Wu M, Ouyang Q, Kong FS, Yang G. Fragment Autoantigens Stimulated T-Cell-Immunotherapy (FAST) as a Fast Autologous Cancer Vaccine. Adv Sci (Weinh). 2025 Jul;12(26):e2502937. doi: 10.1002/advs.202502937. Epub 2025 Mar 26. PMID: 40135850; PMCID: PMC12245027.
48. Chen F, Zhou P, Ren G, Lee EKW, Liu Q, Shen Y, Wang Y, El Helali A, Jin JY, Fu P, Dai W, Lee AWM, Yu H, Spring Kong FM. Interpretable deep learning insights: Unveiling the role of 1 Gy volume on lymphopenia after radiotherapy in breast cancer. Radiother Oncol. 2024 Aug;197:110333. doi: 10.1016/j.radonc.2024.110333. Epub 2024 May 19. PMID: 38772478.
49. Zhang L, Yin FF, Li T, Teng X, Xiao H, Harris W, Ren L, Kong FS, Ge H, Mao R, Cai J. Multi-contrast four-dimensional magnetic resonance imaging (MC-4D-MRI): Development and initial evaluation in liver tumor patients. Med Phys. 2021 Dec;48(12):7984-7997. doi: 10.1002/mp.15314. Epub 2021 Nov 18. PMID: 34706072; PMCID: PMC9016486.
50. Chen F, Yu H, Zhang H, Nong Y, Wang Q, Jing H, Han Y, Wu J, Zhou Z, Yang L, Xu Z, Liu Y, Fu P, Jin JY, Hsue V, Chang A, Kong FS. Risk factors for radiation induced lymphopenia in patients with breast cancer receiving adjuvant radiotherapy. Ann Transl Med. 2021 Aug;9(16):1288. doi: 10.21037/atm-21-2150. PMID: 34532425; PMCID: PMC8422134.
51. Jin JY, Yuan J, Qin X, Li Y, Yan H, Oleinick NL, Yao M, Pan Q, Kong FS, Machtay M. Derivation of a comprehensive semi-empirical proton RBE model from published experimental cell survival data collected in the PIDE database. Front Oncol. 2024 Nov 27;14:1415213. doi: 10.3389/fonc.2024.1415213. PMID: 39664177; PMCID: PMC11631728.
52. Qin X, Li Y, You P, Zhu Y, Wang J, Wang G, Tian C, Spring Kong FM, Zha H, Ma T, Jin JY. Local FLASH radiation exhibits a double-edged effect on the mouse immune system. Radiat Oncol. 2026 Mar 4;21(1):53. doi: 10.1186/s13014-026-02810-3. PMID: 41782029; PMCID: PMC13069716.
53. Wong NSM, Lee FAS, Lee VWY, Chan KS, Yu Yeung CS, Ho CHM, Yip WWL, Chiu KWH, Chan MKH, Wong FCS, Kong FS, Chiang CL. Long-Term Outcome of Stereotactically Designed Hypofractionated Image Guided Radiation Therapy in Large, Unresectable Hepatocellular Carcinoma. Pract Radiat Oncol. 2025 Nov-Dec;15(6):e581-e596. doi: 10.1016/j.prro.2025.05.016. Epub 2025 Sep 20. PMID: 40974368.
54. Kong FS, Hu C, Bradley JD, Machtay M. Reply to: Mid-Treatment Positron Emission Tomography-Adaptive Radiotherapy in Stage III Non-Small Cell Lung Cancer: Another Attempt Toward Personalized Care. J Clin Oncol. 2025 Jun;43(16):1936-1937. doi: 10.1200/JCO-25-00069. Epub 2025 Mar 21. PMID: 40117519.
55. Cheung BMF, Lau KS, Lee VHF, Leung TW, Kong FS, Luk MY, Yuen KK. Computed tomography-based radiomic model predicts radiological response following stereotactic body radiation therapy in early-stage non-small-cell lung cancer and pulmonary oligo-metastases. Radiat Oncol J. 2021 Dec;39(4):254-264. doi: 10.3857/roj.2021.00311. Epub 2021 Oct 26. PMID: 34986546; PMCID: PMC8743458.
56. Zhang H, Wang W, Pi W, Bi N, DesRosiers C, Kong F, Cheng M, Yang L, Lautenschlaeger T, Jolly S, Jin J, Kong FS. Genetic Variations in the Transforming Growth Factor-β1 Pathway May Improve Predictive Power for Overall Survival in Non-small Cell Lung Cancer. Front Oncol. 2021 Jul 7;11:599719. doi: 10.3389/fonc.2021.599719. PMID: 34307117; PMCID: PMC8294034.
57. Chiang CL, Chiu KW, Lee FA, Kong FS, Chan AC. Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Front Oncol. 2021 Dec 7;11:798832. doi: 10.3389/fonc.2021.798832. PMID: 34950594; PMCID: PMC8688536.
58. Jin JY, Hu C, Xiao Y, Zhang H, Paulus R, Ellsworth SG, Schild SE, Bogart JA, Dobelbower MC, Kavadi VS, Narayan S, Iyengar P, Robinson C, Greenberger JS, Koprowski C, Machtay M, Curran W, Choy H, Bradley JD, Kong FS. Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617. Cancers (Basel). 2021 Dec 8;13(24):6193. doi: 10.3390/cancers13246193. PMID: 34944813; PMCID: PMC8699524.
59. Zhong S, Wang G, Qin X, Li Y, Sun B, Kong FS, Gao Y, Jin JY. A Statistical Approach to Assess Biological Equivalent Mean Organ Dose (MOD) for Different Fractionations in Thoracic Radiotherapy. Biomedicines. 2025 May 2;13(5):1110. doi: 10.3390/biomedicines13051110. PMID: 40426936; PMCID: PMC12109231.
60. Li S, Zheng X, Meng Y, Chen G, Zhao C, Zhong S, Li H, Bai R, Dong Y, Kong FS. Prophylactic Cranial Irradiation in MRI-Staged Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Survival and Neurocognitive Outcomes. Cancers (Basel). 2026 Jun 17;18(12):1970. doi: 10.3390/cancers18121970. PMID: 42352503; PMCID: PMC13296764.
61. Wang SC, Ye ZH, Zhou H, Zhao ZR, Zhou YH, Huang SJ, Gao Z, Zhou ZH, Zheng DY, Meng YN, Lee TTL, Wai AKC, Kong FS. Differential survival impact of acetaminophen and non-steroidal anti-inflammatory drugs on NSCLC patients undergoing immune checkpoint inhibitor therapy: a region-wide cohort study in Hong Kong, China. J Natl Cancer Cent. 2026 Feb 15;6(2):185-188. doi: 10.1016/j.jncc.2026.02.003. PMID: 42007217; PMCID: PMC13083622.